Deferoxamine (DFO): the effectiveness for noninvasive diagnosis of aluminum-related bone disease, and for treatment of the disease.
D000535:Aluminum / Q000009:adverse effects* / Q000032:analysis; D001847:Bone Diseases / Q000139:chemically induced* / Q000175:diagnosis / Q000188:drug therapy; D001842:Bone and Bones / Q000032:analysis; D002117:Calcitriol / Q000494:pharmacology; D002118:Calcium / Q000032:analysis; D003638:Deafness / Q000139:chemically induced; D003676:Deferoxamine / Q000009:adverse effects / Q000627:therapeutic use*; D005123:Eye / Q000187:drug effects; D006801:Humans; D006435:Renal Dialysis / Q000009:adverse effects; D014511:Uremia / Q000628:therapy
D000535:Aluminum; D002117:Calcitriol; D003676:Deferoxamine; D002118:Calcium